Type I interferon blockade in systemic lupus erythematosus: where do we stand?
about
Interferon alpha on NZM2328.Lc1R27: enhancing autoimmunity and immune complex-mediated glomerulonephritis without end stage renal failureInterferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study.Blood gene expression profiling in pediatric systemic lupus erythematosus and systemic juvenile idiopathic arthritis: from bench to bedside.AGS, SLE, and RNASEH2 mutations: translating insights into therapeutic advancesPathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedsideAnimal Models of Interferon Signature Positive Lupus.Negative regulation of TLR signaling in myeloid cells--implications for autoimmune diseases.Immunoinflammatory diseases of the central nervous system - the tale of two cytokines.Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.Clash of the Cytokine Titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses.Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus ErythematosusTargeting interferons in systemic lupus erythematosus: current and future prospects.Lupus erythematosus revisited.Upcoming Therapeutic Targets in Cutaneous Lupus Erythematous.Advances in the treatment of cutaneous lupus erythematosus.Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus.Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus.Detection of interferon alpha protein reveals differential levels and cellular sources in disease.Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification.Structural basis of the broadly neutralizing anti-interferon-α antibody rontalizumab.Enhanced IFN-α production is associated with increased TLR7 retention in the lysosomes of palasmacytoid dendritic cells in systemic lupus erythematosusA novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features.Complex disease=complex trial? Lessons from a successful trial of anti-IFNα in SLE.Conventional DCs from Male and Female Lupus-Prone B6.NZM Sle1/Sle2/Sle3 Mice Express an IFN Signature and Have a Higher Immunometabolism That Are Enhanced by Estrogen.Vitamin D supplementation effects on FoxP3 expression in T cells and FoxP3+/IL-17A ratio and clinical course in systemic lupus erythematosus patients: a study in a Portuguese cohortThe Prospects of an Active Vaccine Against Asthma Targeting IL-5
P2860
Q30410652-FEEE77D5-FFFA-4204-8F80-4B20D98F6C04Q31111222-FEF7D7FD-D448-464C-A204-47904D3A36A5Q33622723-1B78D329-F69C-474B-B79C-004A149A08ACQ35242554-B64A4471-B874-4CB9-859F-00F587ADE6F7Q35309470-A67FDD45-105B-41FC-815C-027FA29A4B1BQ35686914-71C44A0F-AE94-4FB0-88CA-79A5ED17530FQ36437284-7365AAA6-273A-4D14-8095-F44C59F06B89Q36547012-5908073A-3DCC-4271-BAB4-E13C68E3061EQ37398870-842D9BC8-5B88-40D3-8833-578A2F2A57B9Q37559660-9D61473B-CF1C-46A5-9F6D-2AD21ED09AD0Q37633408-7D724794-3A95-49F3-A91F-8F3A1E8C1EFDQ38458846-601BF70E-7A82-4348-979A-6F126AB786E8Q38659241-343DE29A-F8EF-4844-BC4D-62A1FEACD555Q38708002-AD0BDFC2-18AD-4E04-BF4E-B1EFE96C45FAQ38851093-E2E96CAD-79E2-4782-B04E-ECE1140EF4DDQ38888137-236DC41F-A843-4996-8FA8-09A6D980EAC0Q39045512-8ABC9D96-E9E1-4134-AB06-1AA37C38172FQ40237578-1DFF1D2B-7A3C-4952-8176-3A12292E6F38Q40795030-BAD2D59B-8ADB-4D19-8364-84210304627EQ41146376-F36F6877-7D7C-486E-92F2-196EBDB50268Q42668884-7AB75BDA-F812-46DA-9BBB-0F89A22F50BEQ52593114-FF9404AA-9257-4126-B7B3-5ED9930AB900Q53035901-610C96F5-C1F2-4A3D-A2B0-20009AEA3E8EQ55361040-9D466B45-0A10-4E91-BBF7-29AABAD6EEEDQ57526158-4622E509-08B9-444C-89FC-1311EA1051D4Q58566763-71E06BD1-C527-4D33-841B-D90BE56C68DF
P2860
Type I interferon blockade in systemic lupus erythematosus: where do we stand?
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Type I interferon blockade in systemic lupus erythematosus: where do we stand?
@ast
Type I interferon blockade in systemic lupus erythematosus: where do we stand?
@en
Type I interferon blockade in systemic lupus erythematosus: where do we stand?
@nl
type
label
Type I interferon blockade in systemic lupus erythematosus: where do we stand?
@ast
Type I interferon blockade in systemic lupus erythematosus: where do we stand?
@en
Type I interferon blockade in systemic lupus erythematosus: where do we stand?
@nl
prefLabel
Type I interferon blockade in systemic lupus erythematosus: where do we stand?
@ast
Type I interferon blockade in systemic lupus erythematosus: where do we stand?
@en
Type I interferon blockade in systemic lupus erythematosus: where do we stand?
@nl
P2093
P2860
P3181
P356
P1433
P1476
Type I interferon blockade in systemic lupus erythematosus: where do we stand?
@en
P2093
B. R. Lauwerys
F. A. Houssiau
J. Ducreux
P2860
P304
P3181
P356
10.1093/RHEUMATOLOGY/KET403
P407
P577
2014-08-01T00:00:00Z